Intarcia Therapeutics Stock
Intarcia Therapeutics is a biopharmaceutical company developing therapies for diseases that require long-term chronic treatment.
Sign up today and learn more about Intarcia Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Intarcia Therapeutics Stock
Intarcia Therapeutics, Inc. is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. The company's products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. The company was formerly known as BioMedicines, Inc. and changed its name to Intarcia Therapeutics, Inc. in September 2004. Intarcia Therapeutics was founded in 1997 and is based in Hayward, California with an additional office in Mountain View, California.
Investors
Pritzker Group Venture Capital
Scopely, Intarcia Therapeutics, project44, The Honest Company, Casper, Cameo, Heal, G2
Funding History
| May 2010 | $14.5M |
|---|---|
| September 2010 | $5.0M |
| January 2012 | $83.7M |
| August 2012 | $45.8M |
| November 2012 | $160M |
| November 2012 | $50.0M |
| April 2014 | $200M |
| April 2015 | $225M |
| May 2016 | $75.0M |
| September 2016 | $215M |
Management
CFO & Vice President, Finance and Operations
James M. Ahlers
Vice President, Global Regulatory Affairs and Quality
Sunita Zalani
Vice President, General Counsel, and Chief Legal Officer
Raymond Keane
Vice President, Human Resources
James P. Brady
Head of Customer Experience & Outcomes (CXO)
Jay Smith
Executive Director, DUROS® Manufacturing
Dick Ford
Chief Operating Officer
Michael Williams
Vice President, Chief Scientific Officer
Andrew Young
Head of Discovery and Translational Medicine
Paul Feldman
Vice President, General Counsel, Corporate Secretary
Barbara McClung
Press
wsj - Nov, 22 2021
Intarcia Therapeutics Takes One Last Shot at FDA Approvalstatnews - Jan, 13 2021
After repeated FDA rejections, key investor writes down stake in former diabetes unicorn Intarcia Therapeuticstechstartups - Nov, 20 2020
Unicorn startup companies 2020: List of top 500 unicorn startups with valuation of $1 Billion+massdevice - Oct, 16 2019
Intarcia Therapeutics takes another run at FDA approvalbusinesswire - Mar, 7 2019
Numab Announces Entry into a License Agreement With Intarcia for Anti-Inflammatory ND016bioportfolio - Jan, 9 2019
Intarcia Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250businesswire - Nov, 18 2018
Researchers Have 3 Suggestions to Close the Gaps When Creating Value Frameworks for New Medical Therapiesbusinessinsider - Oct, 29 2018
The 25 most valuable private tech companies in the USbusinesswire - Sep, 21 2018
Numab Appoints Immunotherapy Pioneer Ignacio Melero as Scientific Advisorbusinesswire - Aug, 3 2018
Sobi Names Jeff Henderson Vice President, Head of Market Access and Government Affairs, U.S.prnewswire - Jun, 18 2018
Intarcia Provides Corporate Updatexconomy - Apr, 4 2018
Macrolide Pharma Raises $20M, Names Former Intarcia Exec Karande CEOfiercebiotech - Feb, 6 2018
Months after FDA rejection, Intarcia cuts 60 jobs and halts 2 late-stage trialsprnewswire - Dec, 19 2017
Aytu BioScience Announces Appointment of David Green as Chief Financial Officerxconomy - Nov, 5 2017
VC Funding Surges in Fewer Deals in Third Quarter, and Top 10 Dealsfortune - Sep, 29 2017
Russia Investigation: Twitter Banned 200 Fake Accounts But Left Key Details Outbostonglobe - Sep, 29 2017
FDA balks at Intarcia’s diabetes drug pumpprnewswire - Sep, 16 2017
New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetesstartupticker - Sep, 15 2017
Intarcia and Numab Reach Key Milestonexconomy - Jul, 14 2017
VC “Self-Correction” Continues in Second Quarter, and Top 10 Dealscbinsights - Feb, 17 2017
The Big Slide: VC Funding To US Startups Dropsprnewswire - Feb, 5 2017
Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetesmedcitynews - Jan, 30 2017
Venrock raises a comfortable $450M for fund 8prnewswire - Jan, 29 2017
Global Implantable Infusion Pumps Market 2016-2025: $14.33 Billion Growth Opportunities/Investment Opportunities - Research-and-Marketscbinsights - Jan, 23 2017
$1B+ Market Map: The World’s 183 Unicorn Companies In One Infographicstrictlyvc - Jan, 15 2017
StrictlyVC: January 3, 2017xconomy - Jan, 10 2017
Bio Roundup: Biogen Price Fears, A Grail Billion, Hellos, Byes & Moreprnewswire - Jan, 8 2017
Intarcia Therapeutics Announces Upcoming Presentation at 35th Annual J.P. Morgan Healthcare Conferencemassdevice - Jan, 1 2017
MassDevice.com +5 | The top 5 medtech stories for December 29, 2016finsmes - Jan, 1 2017
Intarcia Therapeutics Raises $206M in Second Close of Series EE Financingxconomy - Jan, 1 2017
Gates Foundation Sends $140M to Intarcia for HIV Version of Pumpmedcitynews - Jan, 1 2017
Private biotech funding has skyrocketed, so why bother going public?prnewswire - Dec, 31 2016
Intarcia Secures Second Close of the Series EE Equity Financing for an Additional $206M; As Part of the Financing and a New Strategic Initiative, Intarcia Now Aims Its Medici Technology Towards Preventing HIVmedcitynews - Dec, 25 2016
8 healthcare companies make U.S. unicorn list. Theranos is not one of themcbinsights - Nov, 24 2016
The Fastest Unicorns: From First Financing to Billion Dollar Valuations- Oct, 14 2016
These are the top 10 life sciences VC deals in Q3- Jun, 1 2016
Type 2 Diabetes Market Pipeline Covering 221 Companies for H1 2016 Reviewed in New Research Reportcbinsights - May, 27 2016
Healthcare Startup Boom: 2015 Could See More Than $12B Invested Into VC-Backed Companiesbizjournals - May, 10 2016
Intarcia clears final trial hurdle before seeking FDA approval, plans hiring pushprnewswire - Apr, 26 2016
Asia-Pacific Type 2 Diabetes Mellitus Therapeutics in Markets to 2021 - Markets is Expected to Increase in Value at a CAGR of 7.7%, from $6.07 Billion to Over $10.2 Billion - Research and Marketsstrictlyvc - Apr, 5 2016
StrictlyVC: March 31, 2016prnewswire - Apr, 4 2016
Global Biotherapeutics Market Report: Novel Formulation and Delivery Approaches with Focus on Antibodies and Proteins - Research and Marketsprnewswire - Apr, 4 2016
Global Biotherapeutics Market Report: Novel Formulation and Delivery Approaches with Focus on Antibodies and Proteins - Research and Marketsprnewswire - Mar, 7 2016
Peptide Therapeutics in Metabolic Disorders, 2016 - 2025prnewswire - Jan, 8 2016
Intarcia Therapeutics Announces Upcoming Presentation at 34th Annual J.P. Morgan Healthcare Conferencewraltechwire - Jan, 2 2016
Review NC's top life science stories in 2015: The acquisitionsfortune - Dec, 31 2015
Fidelity Just Revalued Dropbox, Snapchat, and More Tech Startupswraltechwire - Nov, 26 2015
New Alexandria Center to change RTP's innovation, physical landscapebusinesswire - Nov, 10 2015
Seres Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Updateblogs - Nov, 5 2015
Uber, Cloudera, Pinterest — Fidelity Sees Big Gains From Hot Startupstheventurealley - Nov, 3 2015
Recap of Q2 2015 Venture Capital Activity by Regionmassdevice - Sep, 29 2015
Diabetes: Intarcia’s implantable drug pump tops Merck’s Januviaxconomy - Sep, 29 2015
Intarcia Therapeutics Garners $22,019,245 New Fundingxconomy - Sep, 29 2015
Radius Health, Still Private, Raises Another $43Mmassdevice - Sep, 29 2015
Intarcia adds $225m for Type II diabetes trialbloombergview - Sep, 29 2015
Benner on Tech: Apple's Happy Shareholders and Twitter's Earningsmassdevice - Sep, 29 2015
Intarcia raises $225m to fund diabetes trial | Medtech funding for the week of April 27, 2015prweb - Sep, 29 2015
The SGNY Group Wins Platinum Hermes Creative Awardbetaboston - Sep, 29 2015
What’s exciting in Boston right now?massdevice - Sep, 29 2015
Diabetes: Medtronic furthers the quest for an artificial pancreasprnewswire - Sep, 29 2015
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Study 2015xconomy - Sep, 29 2015
Intarcia Snags $210M to Push Implantable Device for Diabetesmassdevice - Sep, 29 2015
GI Dynamics slashes workforce by 46%massdevice - Sep, 29 2015
Ivenix raises $42m for drug infusion technologymassdevice - Sep, 29 2015
Philips Healthcare’s India chief takes over new emerging markets biz | Personnel Movesmassdevice - Sep, 29 2015
Medtronic signs 10-year deal with Minnesota Vikingsmassdevice - Sep, 29 2015
Update: QualComm buys Capsule, looks to ‘internet of medical things’massdevice - Sep, 29 2015
Foresite Capital secures $300M for late-stage healthcare investment fundfinsmes - Sep, 29 2015
Foresite Capital Closes Second Fund at $300Mmassdevice - Sep, 29 2015
Funding: Medtech VC jumps in Q2, but not for early-stage companiesfiercebiotech - Sep, 29 2015
Intarcia's annual diabetes treatment aces two Phase III trialsfiercebiotech - Sep, 29 2015
Servier gambling up to $1B-plus on Intarcia's PhIII diabetes drug/devicebetaboston - Sep, 29 2015
Unicorns among us: Bonus material on companies with $1 billion-plus valuationsfiercemedicaldevices - Sep, 29 2015
Med tech makes the WSJ billion-dollar startup club: Theranos, Intarcia and Proteusmassdevice - Sep, 29 2015
Tandem Diabetes plans $60m offering | Medtech funding for the week of March 2, 2015prnewswire - Sep, 29 2015
Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Reportfiercemedicaldevices - Sep, 29 2015
Diabetes research advocacy groups call for better insulin pump regulationbusinesswire - Sep, 29 2015
Research and Markets: Global Obesity Therapeutics Pipeline Review 2015 - Featuring 94 Companiesxconomy - Jul, 30 2015
Foresite Capital Keeps Late-Stage Healthcare Focus With $450M Third Fund | Xconomyxconomy - May, 22 2015
Intarcia Bets It Will Shake Up Diabetes Treatment With Implantable Device | Xconomyxconomy - May, 22 2015
Look Who’s Hiring in Biotech: Companies That Are Built to Last | Xconomytechworld - May, 21 2015
UK tech giant Pace gets snapped up, Time Warner Cable deal set to be canned, Apple Watch launch winners and losers and other important technology deals this weekxconomy - May, 21 2015
Servier Inks $1B Deal for Intarcia’s Implantable Diabetes Device | Xconomyventurebeat - May, 20 2015
VC investments slide in Q4 and decline for all of 2012 | VentureBeat | News | by Dean Takahashithenextweb - May, 20 2015
VC Funding in Q4 2012 Decreased, But More Mobile and Healthcare Dealsxconomy - Apr, 28 2015
Intarcia, Still Private, Nabs $225M More For Diabetes Device | Xconomyxconomy - May, 27 2014
Foresite Capital Reloads With New $300M Late-Stage Biotech Fund | Xconomyxconomy - May, 27 2014
Foresite Capital Closes $100M Fund for Late-Stage Biotechsventurebeat - May, 22 2014
Health care venture firm Foresite Capital closes $300M fundfinsmes - Apr, 2 2014
FinSMEs | Intarcia Therapeutics Raises $200m FinancingEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
